Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the TOUCH® Prescribing Program - 27/03/19
Résumé |
Introduction |
Natalizumab, approved for 300mg intravenous every-4-weeks dosing, is associated with PML risk.
Objectives |
To determine whether natalizumab EID is associated with reduced PML risk compared with SID.
Patients and methods |
Average dosing intervals (ADIs) were≥3 to<5 weeks for SID and>5 to≤12 weeks for EID. The primary analysis assessed ADI in the last 18 months of infusion history. The secondary analysis identified any prolonged period of EID at any time in the infusion history. The tertiary analysis assessed ADI over the full infusion history.
Results |
In primary analyses, median exposure (months) was 44 for SID and 59 for EID. The PML HR (95% confidence interval) was 0.06 (0.01–0.22; P<0.001) for primary and 0.12 (0.05–0.29; P<0.001) for secondary analyses; no EID PML cases were observed in tertiary analyses (Kaplan–Meier log-rank test P=0.02).
Discussion |
NA.
Conclusion |
In JCV Ab+patients, natalizumab EID is associated with a clinically and statistically significant reduction in PML risk as compared with SID.
Le texte complet de cet article est disponible en PDF.Keywords : PML, EID, Natalizumab
Plan
Vol 175 - N° S1
P. S102 - avril 2019 Retour au numéro
Article précédent
- Real-world data from over 10 years in the TYSABRI® Observational Program: Long-term safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients
- Ludwig Kappos, Helmut Butzkueven, Tim Spelman, Maria Trojano, Heinz Wiendl, Xiaoyu Jiang, Rachna Kasliwal, Nolan Campbell, Pei-Ran Ho, Stephanie Licata
- Fluctuations non motrices chez le patient parkinsonien : validation d’une échelle d’hétéro-évaluation diagnostique
- Florent Faggianelli, Tatiana Witjas, Anderson Loundou, Karine Baumstarck, Pascal Auquier, Nathalie Semeriva, Jean-Philippe Azulay
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?